Page 213 - Genentech News Today

Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development - read this article along with other careers information, tips and advice on BioSpace

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.The overall response rate was 54% in younger patients and 72% in older patients, Adam J. Olszewski, MD, presenting author, said.

/PRNewswire/ -- The Broad Institutes Cancer Dependency Map Consortium, an academic-industrial partnership program that was first announced in 2019, is...

/PRNewswire/ -- Blue Matter is pleased to announce that it has hired Prasanna Sridharan as a Partner in its San Francisco office. Prasanna will join the firms...

The respiratory syncytial virus market is expected to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast

/PRNewswire/ -- DelveInsights Respiratory Syncytial Virus Market Insights report includes a comprehensive understanding of current treatment practices,...

Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bid to targets previously deemed undruggable.

Cervical Cancer Awareness Month is observed every January.An estimated 14,100 new cases of invasive cervical cancer are diagnosed in the United States annually, and approximately 4,280 women will die of the disease this year, according to American Cancer Society.

PR industry veterans Emily Poe and Curtis Sparrer identified adopting AI as a tool for performing a higher level of work and focusing on big picture moments like a spot on the

Among many objectives, the project will perform whole-genome sequencing of 10,000 individuals to build out its reference genome set.